Sloppy Research Extracts A Greater Toll Than Misconduct

There has been much ado about fraud in science, and even more misunderstanding about its eventual importance in the efficient conduct of science, and our ability to police it. A report on a survey by Judith Swayze was headlined in the New York Times "... the myth that fraud in science is a rarity" (L.K. Altman, Nov. 23, 1993, page C3). In fact, as the text of the story took pains to emphasize, the study found that a majority of interviewees had heard of an example--in other words, that some fra

Written byJoshua Lederberg
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The promulgation of fraud is an outrage, striking at the moral roots of the scientific enterprise. But its moral stridency is large, I submit, compared to its practical importance in most scientific fields. A much larger toll is exacted from inadequate experimental design and sloppy execution. The lost effort that is expended in straightening out muddy claims, or merely in plowing through their presentation in the literature, greatly exceeds what can be attributed to intentional fraud.

We do not rely entirely on the intrinsic virtue of the scientific personality. We are all human, and not equally socialized into the deepest respect for the truth, nor equally well trained to avoid even simple logical and statistical fallacies. It is the scientific system of organized skepticism, to borrow Robert K. Merton's phrase, that maintains the integrity of the enterprise.

Scientific claims enter into a cognitive network of great complexity. Rarely is work ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies